Home  »  Companies   »  Revance Therapeutics Inc. (RVNC): These Numbers Sh...

Revance Therapeutics Inc. (RVNC): These Numbers Show Where NASDAQ:RVNC Stock Is Going Next

Revance Therapeutics Inc. (NASDAQ: RVNC) is 75.30% higher on its value in year-to-date trading and has touched a low of $11.27 and a high of $34.22 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RVNC stock was last observed hovering at around $33.51 in the last trading session, with the day’s loss setting it -1.15% off its average median price target of $31.50 for the next 12 months. It is also 50.22% off the consensus price target high of $65.00 offered by 13 analysts, but current levels are -70.32% lower than the price target low of $19.00 for the same period.

Currently trading at $32.36, the stock is 34.61% and 42.40% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.49 million and changing -3.43% at the moment leaves the stock 61.73% off its SMA200. RVNC registered 140.95% gain for a year compared to 6-month gain of 102.12%.

5 Undervalued Stocks For 2023

Approximately 544 miles north of Las Vegas lies what's been dubbed "the biggest lithium deposit in the US." One tiny company stands to be the biggest beneficiary because lithium "faces a long-term supply shortage," according to Barron's. This company, however, is sitting on a goldmine opportunity as it plans to produce 30,000 tonnes per annum over the next 3.5 years from this single deposit. Supplying the electric vehicle boom and potentially driving its stock price off the charts. But this is just one of the opportunities we have researched in our free report. The other four companies have just as much potential.

Click here to download your Free Copy…


The stock witnessed a 68.63% loss in the last 1 month and extending the period to 3 months gives it a 38.47%, and is 15.45% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.24% over the week and 7.41% over the month.

Revance Therapeutics Inc. (RVNC) has around 495 employees, a market worth around $2.45B and $108.60M in sales. Distance from 52-week low is 187.13% and -5.44% from its 52-week high. The company has generated returns on investments over the last 12 months (-78.70%).

Revance Therapeutics Inc. (RVNC) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Revance Therapeutics Inc. (RVNC) is a “Overweight”. 13 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 1 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.

Revance Therapeutics Inc. is expected to release its quarterly report on 05/09/2023.The EPS is expected to grow by 14.30% this year.

Revance Therapeutics Inc. (RVNC) Top Institutional Holders

The shares outstanding are 82.27M, and float is at 79.47M with Short Float at 16.44%.

Revance Therapeutics Inc. (RVNC) Insider Activity

A total of 7 insider transactions have happened at Revance Therapeutics Inc. (RVNC) in the last six months, with sales accounting for 7 and purchases happening 0 times. The most recent transaction is an insider sale by Schilke Tobin,the company’sCFO. SEC filings show that Schilke Tobin sold 1,000 shares of the company’s common stock on Jan 20 at a price of $31.00 per share for a total of $31000.0. Following the sale, the insider now owns 57877.0 shares.

Revance Therapeutics Inc. disclosed in a document filed with the SEC on Jan 09 that Schilke Tobin (CFO) sold a total of 3,701 shares of the company’s common stock. The trade occurred on Jan 09 and was made at $27.16 per share for $0.1 million. Following the transaction, the insider now directly holds 58877.0 shares of the RVNC stock.

Still, SEC filings show that on Sep 14, Moxie Dwight (SVP, GC & Secretary) disposed off 11,000 shares at an average price of $27.07 for $0.3 million. The insider now directly holds 31,694 shares of Revance Therapeutics Inc. (RVNC).

Revance Therapeutics Inc. (RVNC): Who are the competitors?

The company’s main competitors (and peers) include Ionis Pharmaceuticals Inc. (IONS) that is trading 34.10% up over the past 12 months and Biogen Inc. (BIIB) that is 32.36% higher over the same period. Johnson & Johnson (JNJ) is 2.09% up on the 1-year trading charts.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts